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The successful expansion of hematopoietic stem and progenitor cells (HSPCs) from umbilical cord blood (UCB)
for transplantation could revolutionize clinical practice by improving transplantation-related outcomes and
making available UCB units that have suboptimal cell doses for transplantation. New cytokine combinations
appear able to promote HSPC growth with minimal differentiation into mature precursors and new agents,
such as insulin-like growth factorebinding protein 2, are being used in clinical trials. Molecules that simulate
the HSPC niche, such as Notch ligand, have also shown promise. Further improvements have been made with
the use of mesenchymal stromal cells, which have made possible UCB expansion without a potentially
deleterious prior CD34/CD133 cell selection step. Chemical molecules, such as copper chelators, nicotinamide,
and aryl hydrocarbon antagonists, have shown excellent outcomes in clinical studies. The use of bioreactors
could further add to HSPC studies in future. Drugs that could improve HSPC homing also appear to have
potential in improving engraftment times in UCB transplantation. Technologies to expand HSPC from UCB and
to enhance the homing of these cells appear to have attained the goal of accelerating hematopoietic recovery.
Further discoveries and clinical studies are likely to make the goal of true HSPC expansion a reality for many
applications in future.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Since the ﬁrst umbilical cord blood transplant (UCBT) was
performed in 1988 to successfully treat a patient with Fan-
coni’s anemia [1], over 2 decades of clinical and preclinical
work have been established umbilical cord blood (UCB) as a
Food and Drug Administrationeapproved source of he-
matopoietic stem and progenitor cells (HSPCs) [2]. To date,
over 30,000 UCBT have been performed worldwide to treat
various blood diseases and genetic disorders. Among all
hematopoietic stem cell transplantations (HSCT) performed
worldwide, approximately 10% of patients undergo UCBTedgments on page 1017.
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ty for Blood and Marrow Transplantation.annually, and this number is expected to plateau in the next
few decades. Compared with use of bone marrow (BM) or
mobilized peripheral blood stem cells (PBSC), the use of UCB
for transplantation has several advantages, including greater
ease of ﬁnding a donor and prompt availability (with over
700,000 units stored worldwide) [3,4]. More importantly,
the greater tolerance across human leukocyte antigen (HLA)
barriers and lower incidence of graft-versus-host-disease
(GVHD) [5] makes UCB an ideal alternative for a signiﬁcant
number of HSCT patients (approximately 40% of Caucasians
and up to 55% to 80% of non-Caucasians) who do not have
access to a HLA-matched donor [6,7]. Furthermore, in several
meta-analyses, UCBT has also been shown to lead to equiv-
alent outcomes to fully matched BM transplantations in both
adult and pediatric patients, thus serving as an effective
donor source for allogeneic HSCT for patients without a
matched sibling donor [8,9].
Table 1
Clinical Strategies to Enhance Expansion and Homing of UCB Grafts
1. Ex vivo expansion
 Hematopoietic cytokines in liquid culture
 SCF, TPO, and Flt-3L is the most potent cocktail for HSPC
maintenance, whereas cytokines such as IL-3, IL-6, IL-11, and
G-CSF rapidly generate differentiated cells. Growth factors
secreted by differentiated cells deter self-renewal capacity of
HSPC.
 Novel growth factors include IGFBP-2, Angptl proteins, and
pleiotrophin.
 MSC cocultures recreate the microenvironment of the BM
 Allogeneic BM-derivedMSC eliminate the need to perform stem
cell selection and control vital functions of HSPC through direct
cell-to-cell contact and proteomic secretion.
 Chemical molecules and proteins that regulate signaling pathways
of HSPC
 Molecules, such as tetraethylenepentamine TEPA (copper
chelator), NAM (sirtuin 1 inhibitor), SR1 (aryl hydrocarbon re-
ceptor antagonist), and immobilized delta-1 (Notch ligand).
 Bioreactors and devices that allows continuous perfusion culture
 Large-scale expansion that maintains an optimal concentration
of the potent cytokines while minimizing inhibitory factors.
2. Homing
 Inhibition of CD26/Dipeptidylpeptidase IV (DPP-4)
 Interfere in the chemotaxis of CD34þ human hematopoietic
cells through DPP-4 enzymatic cleavage in SDF-1.
 Complement fragment 3a (C3a) priming
 Anaphylatoxin C3a receptor, which binds to C3a (modulates
SDF-1 dependent chemotaxis of CD34þ cells) to allow inﬂux of
calcium into the CD34þ cells.
 Dimethyl-prostaglandin E2
 Regulates Wnt pathway via degradation of b-catenin and in-
creases expression of CXCR4.
 Fucosylation
 UCB CD34þ cells exhibit poor homing due to a defect in binding
BM endothelial selectin as its ligand possess inadequate alpha1-
3 fucose required to form glycan determinants, such as sialyl
Lewis x (sLeX).
3. Other clinical strategies
 Choosing UCB unit that has higher TNC dosage and the optimal
HLA match.
 High TNC is the most critical factor in mediating a successful
UCBT; however, it lowers chances of ﬁnding such units for pa-
tients who belong to racial minorities.
 Improving methods of UCB collection along with minimizing post-
thaw cell loss
 Placental perfusion increases collected cells but requires
specialized technical expertise to perform.
 Increasing the number of infused TNC using either dUCB units or a
single UCB unit along with haploidentical CD34þ cells.
 Dual UCB units or coinfusion of haploidentical CD34þ cells en-
hances UCB engraftment but requires complex HLA matching
with potentially increased incidence of GVHD.
 Improved homing by targeted transplantation of UCB graft via
intra-bone or intraosseous infusion
 Compared with i.v. infusion, intraosseous infusion is an invasive
procedure that causes site morbidity.
 Coinfusion with accessory cells, such as allogeneic BM-MSC
 Enhances homing and engraftment of the transplanted HSPC by
creating a suitablemicroenvironment and alleviating symptoms
of GVHD.
 Infusion of mature immune cells derived from part or whole UCB
unit
 Overcomes the current limitation of DLI in UCBT, which could
treat post-transplantation complications, such as relapse,
infections, and GVHD.
TEPA indicates tetraethylenepentamine; DLI, donor lymphocyte infusion.
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recovery, relative to transplants of BM or PBSC, as a conse-
quence of a lower absolute HSPC content [4]. Median time to
neutrophil recovery is typically more than 25 days forunmanipulated UCB grafts versus a median of less than 20
and 24 days, respectively, for PBSC or BM grafts [10,11]. The
profound delay in hematopoietic reconstitution increases
risk of opportunistic microbial and viral infection in the
pancytopenic recipients, thus contributing to the high
transplantation-related mortality of >30% after UCBT [12].
However, the mortality risks appear to be lower with a
higher infused cell dose for transplantation [13].
Current strategies for improving the clinical outcome of
UCBT for adult patients, as outlined in Table 1, focus on
increasing the effective cell dose of the graft in an effort to
enhance hematopoietic cell engraftment. Although the
simultaneous administration of 2 unmanipulated UCB grafts
has demonstrated some possible improvement over single
UCBT, the rate of hematopoietic recovery still remains sub-
optimal, with the reported median time to neutrophil and
platelet repopulation ranging widely between 12 and 32 and
41 and 105 days, respectively [14]. In view of this, approaches
for ex vivo expansion of a single UCB unit to achieve cell
numbers for a successful adult transplantation have been
widely sought after. In this review, we present emerging data
from preclinical and clinical studies of UCB expansion with
recently developed agents (including cytokine combinations,
proteins, and chemicals) in combination with novel strate-
gies, such as the use of mesenchymal stromal cell (MSC)
coculture and bioreactors. Additionally, methods to enhance
homing of UCB to facilitate hematopoietic recovery, as well
as the crucial cellular pathways controlling HSPC survival
and proliferation, will also be discussed. Although some
preclinical data will be reviewed, including animal models
using severe combined immunodeﬁciency (SCID) mice, this
paper will focus mainly on strategies that have been, or are
close to being, brought to clinical trials.RECENT STRATEGIES TO EXPAND UCB GRAFTS
Cytokines
In the past 2 decades, various cytokines have been iden-
tiﬁed to play an important role in regulating HSPC survival,
proliferation, and differentiation [15,16]. Although numerous
studies have attempted to use these factors for HSPC
expansion in vitro, the optimal combination and concentra-
tion are yet to be established, possibly because of the limited
desired effects of these cytokines alone on the target popu-
lation. Today, HSPC expansion cytokine cocktails vary among
the various preclinical and clinical protocols but they
generally include 3 key factors: stem cell factor (SCF),
thrombopoietin (TPO), and Flt-3 ligand (Flt-3L) [17,18]. This
cytokine combination has been shown to maintain he-
matopoietic cell viability [19] and telomere length coupled
with elevated telomerase activity [20], as well as to regulate
expression of adhesion molecules and enhancers of stem cell
expansion [21,22]. The use of other cytokines, such as
erythropoietin, granulocyte colonyestimulating factor (G-
CSF), interleukin 3 (IL-3), interleukin 6 (IL-6), interleukin 11
(IL-11), macrophage colonyestimulating factor, and platelet-
derived growth factor, is more variable and with a tendency
to promote cell differentiation [17,18,23]. For example, IL-3
supports rapid total cell expansion in vitro but the
expanded cells possess reduced in vivo hematopoietic
regenerative potential [24]. An important expansion study by
Levac et al. showed that when the serum-free media were
supplemented with the potent cocktail of SCF, TPO, and Flt-
3L, withdrawal of several differentiation-promoting cyto-
kines, such as IL-3, IL-6, and G-CSF from the expansion
Table 2
Brief Description of Protocols that Enhanced Expansion of UCB Grafts in Completed Clinical Trials
Approach/System Cell Selection of
Manipulated Unit
Growth Factors Infusion of
Unmanipulated Cells
Details of UCB Unit Manipulation Ref.
Cytokine CD34 selected G-CSF, SCF, and MGDF Larger fraction of
the same UCB unit
UCB unit frozen in 2 fractions, 1 of which was
thawed, selected, and expanded for 10 d and
infused into patients followed by the
unmanipulated fraction.
[26]
Continuous
perfusion
culture
Not performed FBS, glutamine, HS,
hydrocortisone, PIXY321,
EPO, Flt-3L
The majority of the UCB unit was transplanted
into the patients, while remaining cells were
expanded for 12 d in the AastromReplicell
system and infused.
[27]
Copper chelation CD133 selected FCS, TPO, IL-6, Flt-3L,
SCF, and TEPA
The smaller fraction was thawed, selected,
and expanded for 21 d and infused into the
patients 24 h after infusion of the
unmanipulated fraction.
[28]
Notch mediated CD34 selected Fibronectin, IL-3, IL-6, TPO,
Flt-3L, and SCF
Separate UCB unit with
higher TNC, which was
transplanted before the
expanded cells
The CD34þ cells from the smaller unit were
cultured for 16 d and transplanted.
[29]
MSC coculture Not performed SCF, Flt-3L, TPO, and G-CSF Smaller UCB unit cocultured with MSC feeder
layer for 7 d, after which the nonadherent cells
were transferred to culture bags while the ﬂasks
were replenished with growth media. On day 14,
all the nonadherent cells in the bags and ﬂasks
were pooled, washed, and transplanted.
[30]
Nicotinamide CD133 selected FBS, Flt-3L, SCF, TPO,
IL-6, and NAM
The CD133þ cells from the smaller UCB unit
were cultured for 19 to 23 d while the
CD133 fraction was cryopreserved. Patients
consecutively received the expanded fraction
and rethawed T cell replete.
[31]
MGDF indicates megakaryocyte growth and development factor; HS, horse serum; EPO, erythropoietin.
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SCID mouse repopulating cells (SRCs) [25].
A clinical trial involving expanded UCB (Table 2), con-
ducted at the MD Anderson Cancer Center, made use of
CD34þ selected cells from a fraction of the graft for expan-
sionwith a combination of SCF, G-CSF, and TPO over a 10-day
period [26]. UCB units with quite low cell doses were used
and the protocol led to a median 4- and 56-fold increase in
the CD34þ and total nucleated cell (TNC) numbers, respec-
tively (Table 4). The study enrolled 37 patients suffering from
hematological malignancies and reported median time to
neutrophil and platelet recovery to be 28 and 106 days,
respectively (Table 5). Approximately 63% of patients
exhibited extensive symptoms of chronic GVHD and only 35%
patients survived beyond 30 months after transplantation.
Recent studies have reported a range of growth factors
that are capable of inducing HSPCs expansion in UCB. Ex-
amples include insulin-like growth factorebinding protein-2
(IGFBP-2) [35], angiopoietin-like (Angptl) proteins [36], and
pleiotrophin [37]. The addition of IGFBP-2 and Angplt5 to
UCB expansion cultures containing SCF, TPO, and ﬁbroblast
growth factor-1 have been demonstrated to signiﬁcantly
increase the number of SRC by 20 fold [35]. Thorough
experimentation demonstrated that IGFBP-2 can synergizeTable 3
Brief Description of Protocols that Enhanced Homing of UCB Grafts in Completed C
Homing Enhancement
Strategy
Infusion of Separate
Unmanipulated UCB
Unit
Details of UCB Unit Manipula
CD26/DPP-4 inhibition No Conventional single unit UCB
Sitagliptin at every 24 h star
C3a priming Yes A UCB unit was primed with
patients without any further
PGE2 exposure Yes The larger of the 2 units was
and infused in the patients f
DPP-4 indicates dipeptidylpeptidase IV; C3a, complement fragment 3a.with neurotrophin-3 to further enhance HSPCs expansion
[38], whereas Angptl-like proteins preserved stem cells
during expansion by binding to the immune-inhibitory re-
ceptor human leukocyte immunoglobulin-like receptor B2
[39,40]. Conversely, Ventura et al. reported that combination
of IGFBP-2 and Angptl-5 impaired short-term lymphoid
reconstitution [41]. Pleiotrophin had a milder expansion ef-
fect on human LinCD34þCD38 cells, which was likely
mediated via the phosphoinositide 3-kinase and Notch
signaling pathways [37]. In an ongoing clinical trial in
Singapore, nonenriched UCB units are expanded in an MSC
coculture system, which is supplemented with IGFBP-2, SCF,
TPO, and Flt-3L for 11 days [42] before infusion into mye-
loablated patients in combination with an unmanipulated
unit. Preliminary data (unpublished) suggest that the
expanded unit is likely to contribute to the long-term he-
matopoiesis (>6 months after transplantation) of the re-
cipients. The complete pilot trial results are expected to be
reported by mid-2015.
There is also recent demonstration that rapidly differen-
tiating cell populations in the expansion culture secrete cy-
tokines and chemokines, such as tumor necrosis factor-a,
macrophage inﬂammatory protein-1a [43], monocyte
chemotactic protein-1 [44], CCL2, CCL3, CCL4, and CXCL10linical Trials
tion and Infusion into Patient Ref.
T where the patients were conditioned with the DPP-4 inhibitor
ting at days -1 to þ2 of the transplantation.
[32]
C3a for 15 min at room temperature and infused into the
washing within 30 min of infusing the unmanipulated unit.
[33]
incubated with PGE2 for 120 min at 37C, which was washed
ollowed by the smaller unmanipulated unit.
[34]
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expansion. It is thought that the inhibitory factors either
negatively regulate HSPCs survival and proliferation or they
alter the function of the stimulatory cytokines. To address
this issue, Zandstra et al. developed a computer-monitored
fed-batch culture system, which targets to maintain the
concentrations of cytokines within an optimal range via
systematic growthmedia dilution [46]. This method led to an
80-fold increase of CD34þ cells in a 12-day expansion culture
with enhanced SRC. Current data suggest that the mere
addition of cytokines may not sufﬁce in achieving the
optimal HSPC growth factor milieu; rather, speciﬁc cytokine
types and their concentrations may need to be tweaked
routinely, depending on culture duration and cell population
composition, to achieve the desired ex vivo expansion effect
[47].
Molecular Simulation of HSPC Niche
Over the years, widespread effort in understanding HSPC
regulation has resulted in the identiﬁcation of a myriad of
potential molecular targets that await further validation for
clinical expansion. Indeed, a number of these have demon-
strated promising effects on UCB cells in the laboratory. The
addition of soluble forms of sonic hedgehog protein to
cytokine-supplemented cultures of human C34þCD38 CB
cells has been shown to increase both primitive repopulating
cells as well as myeloid colony-forming progenitors [48].
Interestingly, this expansion appears to be dependent on
bone morphogenetic protein 4, implicating the bone
morphogenetic protein pathway as a potential target of
intervention. Another signaling target of interest is the Wnt
pathway. An early study by Murdoch et al. showed that
although in vitro exposure of human UCB HSPCs to Wnt-5A
did not affect cell proliferation and differentiation, infusion
of Wnt-5Aecontaining media into mice engrafted with hu-
man repopulating cells gave rise to enhanced multilineage
hematopoietic reconstitution [49]. The molecular mecha-
nisms for Wnt-5A’s effect on HSPCs are not known and need
to be further investigated. Recent studies involving UCB
progenitors have shown that overexpression of Wnt5a,
coupled with inhibition of glycogen synthase kinase-3b,
enhanced in vivo engraftment but failed to increase cell
numbers in expansion cultures. In addition, seminal genetic
studies also showed that overexpression of HOXB4 in human
UCB increased the frequency of both long-term culture-
initiating cells as well as SRC [50]. More importantly, a
similar advantage on human hematopoietic repopulation
was also noted in the nonhuman primate model subse-
quently [51]. Encouraged by these results, researcher’s have
attempted to enhance cellular HOXB4 activity via direct de-
livery of HOXB4 homeoproteins and demonstrated similar
efﬁcacy in expanding UCB cells [52]. It is yet to be deter-
mined whether HOXB4’s potency in human UCB expansion
can be translated into clinical beneﬁts.
Notch-mediated expansion
In-depth studies involving various types of stem cells
have shown that the 5 Notch ligands are essential for
determining self-renewal, survival, and differentiation [53].
Initial studies involving human HSPCs demonstrated the
presence of Notch1 gene in the CD34þ cells [54]. Retroviral
overexpression of Notch1 enhanced the self-renewal capac-
ity of the repopulating cells [55]. Early studies suggested
Jagged-1 to be a novel growth factor for human HSPCs [56].
Although soluble or cell-bound Notch ligand produced
Table 5
Outcome of Completed Clinical Trials Involving Manipulated UCB Grafts
Study Subjects No. of UCB
Units
Infused
Days to
ANC > 500
Days to
Platelet > 20,000
Survival GVHD Engrafting Unit
in Majority of
Patients
Ref.
Cytokine
expansion
37 1 28 (15-49) 106 (38-345) OS at 17 mo, 32% aGVHD at day > 28, 66.7%
cGVHD at day > 100, 74%
NA [26]
Continuous
perfusion
expansion
27 1 22 (13-40) 71 (39-139) EFS at 41 mo, 39%
OS at 100 d, 65%
aGVHD grade 0-I, 63.6%
aGVHD grade II-IV, 36.3%
NA [27]
Copper chelation
expansion
10 1 30 (16-46) 48 (35-105) OS at 100 d, 90% aGVHD grade II, 44.4%
cGVHD at day > 100, 50%
NA [28]
Notch-mediated
expansion
10 2 16 (7-34) Not reported OS at 354 d, 70% aGVHD grade II, 85.7%
aGVHD grade III, 14.2%
Unmanipulated [29]
MSC coculture
expansion
31 2 15 (9-42) 42 (15-62) OS at 1 yr, 32% CI of aGVHD grade II to IV, 42%
CI of aGVHD grade III or IV, 13%
cGVHD, 13%
Unmanipulated [30]
Nicotinamide
expansion
11 2 13 (7-26) 33 (26-49) OS at 1 yr, 82%
PFS at 1 yr, 73%
aGVHD grade II, 50%
cGVHD, 20%
Manipulated [31]
CD26/DPP-4
inhibition
24 1 21 (13-50) 77 (48-220) EFS at 1 yr, 3%
OS at 1 yr, 59%
aGVHD grade II, 5.9%
cGVHD at day > 100, 9.1%
NA [32]
C3a priming 29 2 7 (6-26) Avg. CI of Plt >
20,000 at day
60, 86.5%
NRM CI at 1 yr, 10%
PFS at 1 yr, 52%
Not reported Unmanipulated [33]
PGE2 exposure 12 2 17.5 (14-31) 43 (26-60) PFS at 1 yr, 61.7%
OS at 1 yr, 75%
aGVHD grade I, 25%
aGVHD grade II, 16.7%
cGVHD, 8.3%
Manipulated [34]
ANC indicates absolute neutrophil count; aGVHD, acute GVHD; cGVHD, chronic GVHD; NA, not applicable; EFS, event-free survival; CI, cumulative incidence; Plt,
platelet; NRM, nonrelapse mortality.
S. Bari et al. / Biol Blood Marrow Transplant 21 (2015) 1008e10191012minimal HSPCs expansion, engineered and immobilized
Delta-1, along with ﬁbronectin fragments, produced a 100-
fold expansion of CD34þCD38 progenitors when supple-
mented with a cytokine cocktail of IL-3, Il-6, TPO, FLT-3L, and
SCF [29]. Unlike others, this expansion protocol limited
myeloid differentiation and increased the absolute number
of lymphoid precursors. HSPCs expanded in low concentra-
tions of Notch1 retained the ability to repopulate the non-
obese diabetic (NOD)/SCIDmice, whereas high concentration
promoted apoptosis. In the phase I clinical trial (Table 2), the
16-day expansion of the T celledepleted unit produced 164-
and 562-fold mean expansion of CD34þ and TNC, respec-
tively. The manipulated units with a median CD34þ and TNC
dosage of 6.0  106 and 4.6  107 cells/kg, respectively, were
infused in to the 10 eligible, myeloablated patients along
with an unmanipulated unit (Table 4). This transplantation
procedure proved to be safe, with no reports of engraftment
failures or increased incidence of GVHD. The median time to
neutrophil engraftment was 16 days, which was signiﬁcantly
lower than the control of 26 days (Table 5). Analysis of he-
matopoietic reconstitution in the long-term showed that
only one half of the patients engrafted with the manipulated
unit. This raises concerns that the expansion protocol was
either depleting the HSPCs or was merely assisting in rapid
engraftment of the unexpanded unit [29]. Interim results
from an ongoing multicenter trial involving 23 patients
receiving an unmanipulated graft along with a partially HLA-
matched Notch-expanded UCB showed median neutrophil
and platelet engraftment of 13 and 38 days, respectively,
with overall survival (OS) of 62% at 4 years [57]. The current
data suggest that neutrophil recovery is dependent on the
CD34þ cell dosage and could signiﬁcantly reduce 100-day
nonrelapse mortality. In another ongoing single center trial,
the Notch-expanded UCB is administered as a non-HLA
matched, off-the-shelf cells to boost hematopoietic recov-
ery in the setting of a conventional single or dual UCBT [58].
Provisional data involving 15 patients have shown the me-
dian time for neutrophil and platelet recovery of 19 and 35days, respectively, with no transplantation-related mortality
or grade III and IV acute GVHD [58]. Further investigation of
the myeloablated patients in these 2 ongoing trials has
shown signiﬁcantly reduced risk of bacteremia in the ﬁrst
100 days, likely due to the Notch-expanded graft homing into
the sites of mucosal injury induced by the preparative total
body irradiation [59].Mesenchymal Stromal Cell Coculture
In BM, HSPCs reside in a complex stem cell niche that
provides pivotal cues for its self-renewal, apoptosis, prolif-
eration, and differentiation into mature blood cells [60].
There are at least 3 different types of marrow niches
(endosteal, reticular, and vascular) that impart differential
biological and physiological effects on HSPCs [61]. Within
these HSPC niches, MSC play important hematopoiesis sup-
porting roles and have thus been extensively used in ex vivo
coculture system to recapitulate the natural marrow envi-
ronment [62]. MSC controls vital functions of HSPCs through
direct cell-to-cell contact [63,64], secretion or suppression of
endogenous cytokines and the formation of an extracellular
matrix network [65]. Among the various factors secreted by
MSC, the chemokine CXCL12 (also known as SDF-1) is a
prominent regulator of hematopoiesis and HSPCs homing
[66]. Elevated levels of SDF-1 in MSC coculture system have
resulted in down-regulation of a range of cytokines and
chemokines that promote HSPC differentiation and deter
self-regeneration [67].
The use of a feeder layer coculture system using MSCs
could eliminate the need to perform a prior enrichment of
CD34þ or CD133þ cells to achieve signiﬁcant HSPC expansion
[68]. The major advantages of this are reduced loss of HSPCs
during the selection process and avoidance of the potential
negative effect of positive cell surface marker selection on
HSPC activities. MSCs can be further enhanced to express
surface markers, such as STRO-1 [30] and angiopoietin-
like 5 [69], or genetically manipulated to express
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shown to possess enhanced HSPCs supporting ability [70,71].
In a recently completed dual UCBT (dUCBT) trial (Table 2),
investigators from the MD Anderson Cancer Center per-
formed ex vivo expansion of the smaller UCB unit on a MSC
coculture system in the presence of SCF, TPO, FLT-3L, and
G-CSF and transplanted it with a separate nonmanipulated
unit into 31 myeloablated patients suffering from varying
hematologic malignancies [30]. The MSCs were either
obtained from a related donor via BM aspiration or
an “off-the-shelf” source. The expansion protocol resulted in
12-, 31-, and 17.5-fold increases in the number of TNC,
CD34þ, and colony-forming cells, respectively (Table 4). The
combined transplantation of the expanded and the unex-
panded unit resulted in an increased dosage of TNC, CD34þ
cells, and megakaryocyte progenitors compared with his-
torical unmanipulated dUCBT, resulting in the median times
to neutrophil and platelet engraftment of 15 and 42 days,
respectively (Table 5). This study demonstrated that,
compared with recipients of conventional dUCBT, a higher
proportion of patients achieved cumulative incidence of
neutrophil and platelet engraftment by days 26 and 30,
respectively. However, prolonged follow-up (>6 months) of
the patients showed that only the unmanipulated UCBs
contributed to the long-term donor-derived hematopoiesis,
which is in line with several of the xenotransplantation
studies performed in mice. The cumulative incidence of
acute GVHD (grade III or IV) was observed in 13% of the pa-
tients, whereas 45% demonstrated chronic GVHD [30].
Chemical Molecules
Copper chelator
Studies have shown that the cellular content of copper
could be vital in regulating the proliferation and differenti-
ation of UCB HSPCs [72]. The lack of copper arrested the
differentiation and maturation of hematopoietic cells, with
negligible effect on the development of progenitor cells [73].
Peled et al. performed ex vivo expansion of CD34þCD38
UCB cells in the presence of a known copper chelator, tet-
raethylenepentamine, along with TPO, FLT-3L, IL-6, and SCF,
and saw an 89-fold increase of CD34þ cells that possessed an
enhanced SRC [74,75]. The protocol was implemented in a
phase I/II clinical trial by investigators in the MD Anderson
Cancer Center [28]. Unlike other reported trials, this study
involved only 1 UCB unit that was cryopreserved in 2 frac-
tions (Table 2). Before infusion, CD133þ cells from the
smaller fraction were expanded in culture for 21 days in the
presence of tetraethylenepentamine and resulted in average
increases in TNC and CD34þ cells of 219-fold and 6-fold,
respectively. Myeloablated patients suffering from hemato-
logical malignancies received the nonexpanded fraction fol-
lowed by the expanded fraction (StemEx, Gamida Cell,
Jerusalem, Israel) of the same UCB at a relatively low com-
bined median TNC of 1.8  107 cells/kg (Table 4). Nine of 10
patients achieved UCB engraftment, with median times to
neutrophil and platelet recovery of 30 and 48 days, respec-
tively (Table 5). No signiﬁcant increase in the rates of acute
GVHD (grade III or above) and nonrelapse mortality were
noted. This study established that transplantation of a single
expanded unit was able to attain engraftment with recovery
times comparable to that of traditional single unmanipulated
UCBT [28]. Interim reports from an ongoing multicenter
phase II trial have shown that in 101 patients who under-
went transplantation with the StemEx graft, times to
neutrophil and platelet recovery were 21 and 54 days,respectively, which are signiﬁcantly faster than after con-
ventional dUCBT [76].
Nicotinamide
Recent studies have implicated nicotinamide (NAM) as a
novel agent to expand CD34/CD133-selected UCB cells
in vitro [77]. NAM is a form of vitamin B3 that acts as a potent
inhibitor for both NADþ-dependent enzymes and the sirtuin
family of histone/protein deacetylase [77]. It has been shown
to delay differentiation of the CD34þ cells by inhibiting the
SIRT1 deacetylase. Further investigation revealed that CD34þ
cells cultured in presence of NAM along with TPO, IL-6, FLT-
3L, and SCF possessed an enhanced ability to home and
repopulate NOD/SCID mice and resulted in 9-fold and 7.6-
fold increases in short-term repopulating cells compared
with fresh CD34þ cells and those harvested from NAM-
negative control cultures, respectively [77]. These preclini-
cal data laid the foundation for a small-scale phase I clinical
trial involving 11 patients that was carried out by in-
vestigators in Duke University Medical Center [31]. In the
clinical expansion protocol (Table 2), CD133þ cells from a
single unit of UCB were expanded ex vivo in the presence of
NAM and subsequently coinfused together with the
remaining previously frozen thawed noncultured T cell
fraction from the same UCB unit, along with a second un-
manipulated UCB unit. The expansion resulted in 486-fold
and 72-fold increases of TNC and CD34þ cells, respectively,
resulting in a median transplanted dose of 3.5  106 CD34þ
cells/kg (Table 4). The median times to neutrophil and
platelet engraftment were 13 and 33 days, respectively,
which were signiﬁcantly shorter than the historical controls
(Table 5). Only 2 patients developed chronic GVHD and 5
patients showed acute grade II GVHD, with 1-year OS and
progression-free survival (PFS) rates of 82% and 73%,
respectively, at a median follow-up of 21 months. More
importantly, the expanded UCB unit in this study (NiCord,
Gamida Cell, Jerusalem, Israel) was reported to contribute to
both short-term (<25 days) and long-term (>6 months)
hematopoiesis, which is not commonly observed in other
similar trial designs [31]. Such promising data have now
prompted investigators to initiate a multicenter trial where
patients are designated to receive only the NAM-expanded
UCB without the infusion of the second unmanipulated unit.
Aryl hydrocarbon receptor antagonist
In a recent high throughput screen of an extensive array
of small molecules, Boitano et al. identiﬁed an aryl hydro-
carbon receptor antagonist, StemRegenin 1 (SR1), as a potent
agent for in vitro HSPCs expansion [78]. In contrast to many
of the studied agents, low concentrations of SR1 were found
to induce proliferation only in presence of the cytokine
cocktail (TPO, SCF, FLT-3L, and IL-6), whereas a high con-
centration of it exhibited an antiproliferative response.
In vitro culture of CD34þ cells from UCB in the presence of
SR1 resulted in 669-fold and 17,100-fold expansions in short
(3 week) and long-term (5 week) cultures, respectively.
When the UCB CD34þ cells were expanded for 3 weeks in
SR1 and cytokine-supplemented cultures, the result was a
more than a 10-fold increase in long-term SRC compared
with noncultured or cytokine-expanded controls [78].
Although this study established that aryl hydrocarbon re-
ceptor is implicated in regulating HSPCs activities, the exact
mechanism of action for SR1 is yet to be identiﬁed.
Currently, SR1-expanded UCB (HSC835) is being evalu-
ated in a clinical trial conducted and sponsored by Novartis
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patient receives 2 UCB units: (1) a larger unmanipulated unit,
and (2) a smaller unit that had its CD34þ cells expanded in
culture with SR1 and infused along with the noncultured,
frozen-thawed CD34 fraction. The SR1-supplemented cul-
tures resulted in a median of 328-fold expansion of CD34þ
cells [80]. The median time for neutrophil recovery in all 18
patients was 14.5 days.When HSC835 dominated, neutrophil
recovery occurred at amedian of 10.5 days comparedwith 23
days in patients with unmanipulated graft dominance [80].
The fastest median time for neutrophil recovery of 7 days
was noted in patients with dual myeloid chimerism. Based
on these data, investigators have started to administer
HSC835 as a stand-alone expanded unit, with the ﬁrst 2
patients showing neutrophil recovery at days 8 and 12 [80].
In the future, the trial will evaluate the engraftment potential
of HSC835, which possesses a very high dose of CD34þ cells
in nonmyeloablated patients.
Bioreactor Systems
Several of the technologies for UCB expansion reviewed
above have been developed as static, small-scale systems for
laboratory and early clinical studies. To enable expanded
UCB-based therapies for routine clinical use, the scaling of
these culture systems in an affordable and good
manufacturing practiceerelevant manner, while maintain-
ing its therapeutic potency, is an important technical hurdle
that must be overcome. To achieve this, bioreactors systems
that allow integration of UCB expansion technologies are
currently under development. During culture expansion,
UCB cells are typically suspended in a stirred tank or within
hollow ﬁbers while being supplemented with the necessary
cytokines that are automatically regulated in the presence of
stromal cells or biomaterials [81,82]. A signiﬁcant advantage
of bioreactors compared with static cultures is their ability to
support growth of high cell densities, due to improved
nutrient/waste exchange rates, while regulating global levels
of signaling and growth factors in the culture media. An
example of this is the application of controlled media dilu-
tion during UCB cell culture in a bioreactor [46]. As discussed
above, this approach provided the means for stabilizing
global concentrations of cell-secreted factors such that a
constant ratio of inhibitory to stimulatory factors was ach-
ieved, in contrast to the periodic ﬂuctuations of factor con-
centrations when cells are cultured using a standard media
change protocol. After 12 days in culture, limiting dilution
transplantation analyses showed 7.6-fold versus a 3.6-fold
increase in the number of long-term SRC relative to fresh
cells, for the fed-batch versus complete media change con-
trol, respectively [46]. Such media control strategies in
bioreactor systems are amenable for large-scale cell expan-
sion towards clinical use and can also be combined with
other expansion protocols. The addition of a newly identiﬁed
pyrimidoindole derivative, UM171, which is an agonist of
HSPCs self-renewal to this bioreactor system, further
enhanced in vitro and in vivo expansion of the UCB CD34þ
cells [83].
To date, only 1 clinical study at Duke University Medical
Center evaluated the use of a bioreactor, known as the Aas-
tromReplicell System (Vericel Corp, Cambridge, MA), to
expand a small fraction of an UCB unit (Table 2) [27]. The
majority of the unmanipulated cells from the same unit was
infused into the 27 patients suffering from hematological
malignancies or inherited disorders on day 0 with a median
cell dose of 2.05  107 cells/kg. The expansion cultures weresupplemented with bovine and horse serum, erythropoietin,
FLT-3L, and PIXY321, and the media was continuously
perfused for 12 days into the bioreactor; resulting in 2.4-, 82-
, and .5-fold expansions of TNC, granulocyte-macrophage
colony-forming units, and CD34þ cells, respectively
(Table 4). Although the investigators established the safety
and feasibility of the expanded cells that had median trans-
plantation dosage of 2.05  107 cells/kg, the data did not
suggest an improvement for the rate of hematopoietic re-
covery. The median times to neutrophil and platelet
engraftment were 22 and 94 days, respectively, with about
36% of the evaluable patients developing moderate to severe
GVHD (Table 5) [27]. In this study, the total absolute number
of CD34þ cells was reduced after the expansion compared
with the unmanipulated graft, which could possibly explain
the suboptimal clinical outcome.
RECENT CLINICAL STRATEGIES TO IMPROVE HOMING OF
UCB GRAFTS
A successful UCBT, as determined by the speed of
neutrophil recovery, has been shown to be correlated with
the TNC, CD34, and granulocyte-macrophage colony-forming
unit dosage. However, defective homing of the transplanted
UCB cells also hinders hematopoietic reconstitution and re-
mains to be solved. Homing of HSPCs after conventional
intravenous infusion involves the successful extravasation
and lodging at specialized niches within the BM to allow for
subsequent cell repopulation to occur.
In the past, various strategies to improve homing efﬁciency
of HSPCs have been explored, including intra-bone (i.b.)
infusion of UCB grafts [84,85] and coinfusion of UCB cells with
other accessory cells, such as MSC [86]. A phase I/II study
carried out by San Martino Hospital, Italy involved 32 mye-
loablated patients who received washed UCB grafts via the i.b.
route with median time to neutrophil and platelet recovery of
23 and 36 days, respectively [85]. A subsequent study
involving positron emission topography of 21 i.b. UCBT re-
cipients showed that platelet recovery could be predicted by
the increased ﬂudeoxyglucose (FDG) uptake at the injection
sites [87]. Investigators from University of Minnesota carried
out a dual UCBT in 10myeloablated patients, where 1 unit was
infused via the intravenous route (i.v.) and other was intro-
duced via i.b. injections [88]. Five patients engrafted with i.v.
unit, whereas 4 patients engrafted with the i.b. unit, with
median times to neutrophil and platelet engraftment of 21
and 69 days, respectively [88]. A recently completed trial in
Japan reported neutrophil recovery at a median of 17 days
when unwashed UCB grafts were injected via the i.b. route
into 10 patients receiving reduced-intensity conditioning [89].
A retrospective analysis of single unit i.b. versus dual unit i.v.
UCBT have shown the medial time to neutrophil recovery to
be 23 and 28 days, respectively. Multivariate analysis at 4.7
months after transplantation showed that i.b. UCBT was
associated with lower relapse and GVHD incidence and
improved disease-free survival [90]. These approaches have
only led to moderate improvement in HSPC homing, leaving
room for further development. This section will highlight the
recent developments to enhance HSPC homing to the BM as
an alternative means to increase the overall hematopoietic
repopulation of transplanted UCB cells.
CD26/Dipeptidylpeptidase IV
The cell surface peptidase CD26/dipeptidylpeptidase IV
(DPP-4) has been shown to interfere in the chemotaxis of
CD34þ human hematopoietic cells through DPP-4 enzymatic
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thus incapacitating its chemotactic activity [91,92]. Trun-
cated SDF-1 is unable to activate C-X-C chemokine receptor
type 4 (CXCR4) and also antagonizes signals from full-length
SDF-1 [91]. Murine studies demonstrated that DPP-4 inhi-
bition during G-CSF mobilization resulted in fewer number
of progenitors mobilized into the peripheral blood compared
with controls [93]. Additionally, the inhibition or deletion of
DPP-4 enhanced engraftment of systemically delivered hu-
man CD34þ UCB cells in immunodeﬁcient mice [94]. These
data generated interest in the use of DPP-4 inhibitors to
precondition UCB cells or transplant recipients before cell
infusion.
A recently completed pilot trial evaluated the safety, ef-
ﬁcacy, and feasibility of orally administering a Food and Drug
Administrationeapproved DPP-4 inhibitor, sitagliptin, to
enhance the engraftment of a single-unit UCBT in adults
suffering from hematological malignancies (Table 3) [32]. All
24 patients received a myeloablative conditioning regimen
with sitagliptin administered from day -1 to day þ2 of
transplantation. The infused UCB grafts were red cell
depleted and had amedian cell dose of 3.6 107 cells/kg. The
median time to neutrophil engraftment was 21 days, which
was comparable to historical single UCBT (Table 5). A positive
effect of the sitagliptin treatment to donor UCB cell
engraftment was suggested by the signiﬁcant correlation
between the engraftment of the transplanted cells and the
area under the DPP-4 activity-time curve. The event-free
survival and 1-year OS of the red celledepleted recipients
were 53% and 59%, respectively (Table 5) [32]. This study
demonstrated the modest beneﬁts of CD26 inhibition and
further work is required to optimize the sitagliptin dosing to
achieve further improvements in UCB transplantation
outcomes.
Complement Fragment 3a Priming
Human CD34þ cells express the complement anaphyla-
toxin C3a receptor (C3aR), which binds to C3a to allow inﬂux
of calcium into the cells [95]. Although C3a does not directly
affect the survival and proliferation of HSPCs, it modulates
SDF-1edependent chemotaxis of CD34þ cells [96]. G-CSF
treatment of C3aR and C3 knockout mice showed signiﬁ-
cantly increased mobilization of progenitors in the periph-
eral blood [97]. Similarly, wild-type mice treated with C3aR
antagonist also showed enhanced mobilization [98]. Addi-
tional experiments showed that C3a priming of the CD34þ
cells allowed greater incorporation of CXCR4 receptor into
the lipid rafts, which resulted in improved HSPC homing and
repopulation after transplantation [99,100]. These studies
demonstrated that C3a fragments modulate the responsive-
ness of CXCR4þ HSPCs to the SDF-1 gradient, which is a key
mechanism for HSPC homing into the BM.
A pilot trial included 29 patients with hematological
malignancies who underwent nonmyeloablative condition-
ing and dUCBT with the smaller UCB unit being primed with
commercially available human C3a complement before
infusion (Table 3) [33]. The median TNC doses of the primed
and unmanipulated unit were 1.5  107 and 2.5  107 cells/
kg, respectively, resulting in the median time to neutrophil
engraftment of 7 days, which was faster than the matched
transplantation center historical control of 12 days. Two
thirds of the study patients engrafted with the C3a-primed
unit and had a disease PFS of 52% (Table 5). The cumulative
incidence of nonrelapse mortality at 1 year was 10% [33].
Although the data suggested comparable outcomes withhistorical controls, a large cohort study is required to
establish the beneﬁt of C3a priming of UCBT.
Dimethyl-prostaglandin E2
A screening study of biologically active compounds in
zebra ﬁsh embryos showed that chemicals that enhance
prostaglandin E2 (PGE2) synthesis increased HSPC numbers,
whereas those that block its synthesis have an opposite ef-
fect [101]. Additional mechanistic studies showed that the
Wnt pathway in HSPCs is regulated by PGE2 via degradation
of beta-catenin [102]. Both human and murine HSPCs ex-
press PGE2 receptors and short-term exposure of these cells
to PGE2 increases the cell viability, chemotaxis towards SDF-
1, and proliferative capacity as determined by in vitro func-
tional assays [103]. PGE2 also increased expression of CXCR4
and survivin, which are involved in homing and survival of
HSPCs, respectively [103]. PGE2-treated cells performed
better in competitive transplantation studies andmaintained
serial transplantation capacity. Preclinical studies involving
UCB showed that PGE2 treatment increased the number of
both in vitro colony forming units and in vivo SRCs [104].
However, recent ﬁndings implicated PGE2 treatment with a
transient increase in HSPCs homing and repopulation, as
indicated by serial xenotransplantation experiments [105].
In a recently completed phase 1 trial, 21 patients suffering
from hematological disorders underwent dUCBT after
reduced-intensity conditioning [34]. One of the UCB units
was incubated with PGE2 for at least 1 hour and washed
before infusion into patients whowere divided into 2 cohorts
(Table 3). In the ﬁrst cohort, the smaller UCB unit was
exposed to PGE2 and resulted in median neutrophil
engraftment at day 24, with only 2 of the 9 patients showing
long-term hematopoiesis from the manipulated unit. For the
second cohort, the larger UCB unit was treated with PGE2
that had a median cell dosage of 1.8  107 cells/kg but was
comparable to the unmanipulated smaller unit. The median
time to neutrophil engraftment was 17.5 days, which was at
least 3.5 days earlier than the deﬁned control (Table 5).
Median time for platelet engraftment was 43 days and the
manipulated unit dominated in 9 of the 11 evaluable patients
of cohort 2. Grade I and II acute GVHD was observed in 5
patients, whereas only 1 patient had chronic GVHD. The 1-
and 2-year PFS rates were 61.7% and 31.3%, respectively, and
the 2-year OS rate was 38.9% (Table 5) [34]. Currently a phase
II randomized trial is underway with plans of initiating new
phase I studies, which would involve single-unit UCBT after
PGE2 exposure.
Fucosylation
Extravasation of transplanted hematopoietic cells to the
BM is a multi-step process involving interaction with a
number of cell surface molecules on endothelial cells
including the P- and E-selectins [106]. Binding to selectins
requires the formation of cell surface glycan determinants,
such as sialyl Lewis x (sLeX) via glycoprotein fucosylation
[106]. It was shown that selectin ligands on CD34þ UCB cells
display signiﬁcantly lower levels of alpha 1-3 fucosylation
compared with CD34þ cells from BM or peripheral blood,
leading to reduced binding to the endothelial selectins
[106,107]. This fucosylation deﬁciency has been hypothe-
sized to contribute to a decreased efﬁciency of UCB cells to
home to the BM. Indeed, comparative studies that involved
isolating and transplanting either fucosylated or non-
fucosylated UCB CD34þ cells into NOD scid gamma (NSG)
mice demonstrated that only the fucosylated fraction
Table 6
Ongoing Clinical Trials Involving Manipulated UCB Grafts
Responsible
Organization
ClinicalTrials.gov
Identiﬁer
Estimated
Enrollment
Phase Brief Outline of Ongoing Study Primary Outcome
Gamida Cell Ltd. NCT01590628 10 I/II Cotransplantation of an unmanipulated
UCB graft along with a NAM-expanded
UCB unit (NiCord) for sickle cell disease
patients
(1) Safety, tolerability. and infusional
toxicity of NiCord cells and (2) CI of
donor-derived neutrophil engraftment
NCT01816230 10 I/II A single unit of NAM-expanded UCB,
NiCord, will be transplanted
CI of patient engrafted with
NiCord-derived neutrophil at day
42 after transplantation
Fred Hutchinson
Cancer Research
Center
NCT01690520
(Multicenter)
160 II dUCBT with or without Notch-mediated
ex vivo UCB expansion
Time to engraftment of ANC  500
MD Anderson
Cancer Center
NCT00498316
(Multicenter)
125 I dUCBT where 1 UCB graft is expanded in
presence of a MSC feeder layer compared
to control where patients are receiving both
unmanipulated grafts
Engraftment and time to engraftment
NCT01471067 50 I dUCBT where the larger UCB unit is infused
without any manipulation while the smaller
graft will undergo ex vivo fucosylation
before infusion.
(1) Mean time to engraftment and (2)
No. of patients with engraftment by
day 42
University of
Pennsylvania
NCT00891592 36 I Part of an unmanipulated UCB graft will be
infused while rest of the cells will be ex vivo
expanded to obtain CD3/CD28 costimulated
T cells, which will be coinfused
Grade IV GVHD within 90 d of
transplantation as a measure of
dose-limiting toxicity
Novartis
Pharmaceuticals
NCT01474681 27 I/II dUCBT where the smaller unit is ex vivo
expanded in presence of the small molecule,
SR1, while the larger unit is infused without
any manipulation
Safety and tolerability of HSC835
Singapore General
Hospital
NCT01624701 10 I/II Mesenchymal coculture expanded UCB graft
without prior CD34/CD133 selection will be
transplanted along with an unmanipulated
UCB unit
Safety, infusional toxicities, and
potential immunological competition
Information obtained from ClinicalTrials.gov as December 21, 2014. All trials are for patients with hematological malignancies unless mentioned otherwise.
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In addition, xenotransplantation of UCB CD34þ cells that
endogenously express sLeX demonstrated a signiﬁcantly
higher rate and magnitude of multi-lineage engraftment
compared with sLeX-deﬁcient CD34 cells [108]. To overcome
this inherent fucosylation deﬁciency, several research groups
have attempted to expose UCB CD34þ cells to recombinant
human fucosyltransferase VI (FTVI) or FTVII and its substrate
GDP-fucose to increase the fucosylation level [109,110]. In
comparison, FTVII proved to be better in fucosylating not
only CD34þ cells, but also T and B cells, which could favorably
modulate both GVHD and graft-versus-tumor effects [110].
Preclinical studies have shown that exogenously fucosylated
UCB CD34þ cells contributed to both signiﬁcantly earlier BM
homing and multilineage hematopoietic reconstitution of
sublethally irradiated NSG mice.
In an ongoing dUCBT clinical trial in MD Anderson
Cancer Center, an unmanipulated UCB unit with the higher
cell dosage is being infused into the patients followed by the
smaller unit that has undergone fucosylation using FTVI and
GDP-fucose for 30 minutes [111]. The fucosylation level of
the CD34þ cells in the manipulated unit increased from a
median of 33% to 99%. To date, 10 patients have undergone
this transplantation regimen after a nonmyeloablative
conditioning. The interim median times to neutrophil and
platelet recovery are reported to be 14 and 33 days,
respectively. Among the evaluable patients, 4 had engraft-
ment from the fucosylated smaller unit, whereas 2 patients
engrafted with the larger unmanipulated unit. Initial
observations showed minimal infusion related toxicity and
2 patients developed grade II acute GVHD [111]. Currently,
the study is recruiting patients and the outcome will be
reported in the near future.FUTURE OF EXPANDED UCB IN HSCT
Unmanipulated UCB have already been established as the
preferred choice of HSPCs for transplantation into pediatric
patients. New developments in UCB expansion have trans-
lated into signiﬁcant clinical beneﬁts over the last decades
and are believed to continue to improve in the years to come
for adult transplantation (Table 6). The proliferation of true
hematopoietic stem cells without differentiation is consid-
ered to be the gold standard for achieving an ultimate ex vivo
expansion. However, currently available techniques are likely
expandingmore progenitors rather than true stem cells as, in
most dUCBT studies, long-term hematopoiesis is imparted by
the unmanipulated unit. Nonetheless, expansion and infu-
sion of high-dose hematopoietic progenitors is also an
important achievement as it reduces the period of pancyto-
penia in the UCBT patients; hence, decreasing the chances of
infection-related morbidity and mortality. Also, recent de-
velopments have shown that it is feasible and cost effective
to obtain clinically relevant numbers of differentiated im-
mune cells, such as natural killer [112], regulatory, and
cytotoxic T cells from UCB [113], which could overcome the
current lack of donor lymphocyte infusion in UCBT.
In conclusion, the true expansion of hematopoietic stem
cells can be achieved by addressing some of the burgeoning
questions, which include improved UCB acquisition and se-
lection based on better predictive markers, identiﬁcation of
various speciﬁc cell subsets for applications in different
clinical situations, implementation of an optimal in vitro
expansion condition, as well as the subsequent development
of a cost-effective clinical-scale expansion protocol. Further
development with regards to identifying and regulating
pathways involved in maintaining the viability and sym-
metric stem cell division would further improve HSPCs
S. Bari et al. / Biol Blood Marrow Transplant 21 (2015) 1008e1019 1017expansion. With our increasing understanding of HSPC
biology from the emerging genetic, cellular, and clinical
studies (Table 6), there is no doubt that even better cell
expansion strategies will be devised in near future.ACKNOWLEDGMENTS
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